KR20170128633A - 탈수초성 질환 및 다른 신경계 질환을 앓는 환자에서 신경-인지 및/또는 신경-정신 손상을 개선하기 위한 4-아미노피리딘의 용도 - Google Patents

탈수초성 질환 및 다른 신경계 질환을 앓는 환자에서 신경-인지 및/또는 신경-정신 손상을 개선하기 위한 4-아미노피리딘의 용도 Download PDF

Info

Publication number
KR20170128633A
KR20170128633A KR1020177032919A KR20177032919A KR20170128633A KR 20170128633 A KR20170128633 A KR 20170128633A KR 1020177032919 A KR1020177032919 A KR 1020177032919A KR 20177032919 A KR20177032919 A KR 20177032919A KR 20170128633 A KR20170128633 A KR 20170128633A
Authority
KR
South Korea
Prior art keywords
neuro
aminopyridine
patient
cognitive
weeks
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020177032919A
Other languages
English (en)
Korean (ko)
Inventor
토마스 씨 웨셀
앤드류 블라이트
Original Assignee
아코르다 쎄라퓨틱스 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아코르다 쎄라퓨틱스 인코포레이티드 filed Critical 아코르다 쎄라퓨틱스 인코포레이티드
Publication of KR20170128633A publication Critical patent/KR20170128633A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
KR1020177032919A 2009-08-11 2010-08-11 탈수초성 질환 및 다른 신경계 질환을 앓는 환자에서 신경-인지 및/또는 신경-정신 손상을 개선하기 위한 4-아미노피리딘의 용도 Ceased KR20170128633A (ko)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US23307709P 2009-08-11 2009-08-11
US23306909P 2009-08-11 2009-08-11
US61/233,069 2009-08-11
US61/233,077 2009-08-11
US23987709P 2009-09-04 2009-09-04
US61/239,877 2009-09-04
PCT/US2010/045211 WO2011019845A1 (en) 2009-08-11 2010-08-11 Use of 4-aminopyridine to improve neuro-cognitive and/or neuro-psychiatric impairment in patients with demyelinating and other nervous system conditions

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020127006244A Division KR20120050473A (ko) 2009-08-11 2010-08-11 탈수초성 질환 및 다른 신경계 질환을 앓는 환자에서 신경-인지 및/또는 신경-정신 손상을 개선하기 위한 4-아미노피리딘의 용도

Publications (1)

Publication Number Publication Date
KR20170128633A true KR20170128633A (ko) 2017-11-22

Family

ID=43586462

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020127006244A Ceased KR20120050473A (ko) 2009-08-11 2010-08-11 탈수초성 질환 및 다른 신경계 질환을 앓는 환자에서 신경-인지 및/또는 신경-정신 손상을 개선하기 위한 4-아미노피리딘의 용도
KR1020177032919A Ceased KR20170128633A (ko) 2009-08-11 2010-08-11 탈수초성 질환 및 다른 신경계 질환을 앓는 환자에서 신경-인지 및/또는 신경-정신 손상을 개선하기 위한 4-아미노피리딘의 용도

Family Applications Before (1)

Application Number Title Priority Date Filing Date
KR1020127006244A Ceased KR20120050473A (ko) 2009-08-11 2010-08-11 탈수초성 질환 및 다른 신경계 질환을 앓는 환자에서 신경-인지 및/또는 신경-정신 손상을 개선하기 위한 4-아미노피리딘의 용도

Country Status (17)

Country Link
US (8) US20130053420A1 (enExample)
EP (1) EP2464229B1 (enExample)
JP (2) JP6137833B2 (enExample)
KR (2) KR20120050473A (enExample)
CN (1) CN102143687B (enExample)
AR (1) AR077858A1 (enExample)
AU (1) AU2010282509B2 (enExample)
BR (1) BRPI1003991A2 (enExample)
CA (1) CA2770698C (enExample)
ES (1) ES2563751T3 (enExample)
JO (1) JO3348B1 (enExample)
MX (1) MX2012001814A (enExample)
RU (1) RU2563821C2 (enExample)
TW (2) TW201613585A (enExample)
UY (1) UY32837A (enExample)
WO (1) WO2011019845A1 (enExample)
ZA (1) ZA201201001B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8007826B2 (en) 2003-12-11 2011-08-30 Acorda Therapeutics, Inc. Sustained release aminopyridine composition
US8354437B2 (en) 2004-04-09 2013-01-15 Acorda Therapeutics, Inc. Method of using sustained release aminopyridine compositions
WO2012009204A1 (en) * 2010-07-15 2012-01-19 The Trustees Of Columbia University In The City Of New York Methods for diagnosing and treating concussive disorders
EP2667869A1 (en) * 2011-01-28 2013-12-04 Acorda Therapeutics, Inc. Use of potassium channel blockers to treat cerebral palsy
CA2840591A1 (en) 2011-06-30 2013-01-03 Biomarin Pharmaceuticals, Inc. Methods of administering 3,4-diaminopyridine
US10905663B2 (en) 2013-03-05 2021-02-02 The University Of Chicago Treatment of demyelinating disorders
WO2014172266A1 (en) * 2013-04-15 2014-10-23 Acorda Therapeutics, Inc. Methods for treating sensorimotor impairments associated with certain types of stroke using aminopyridines
DE102014221687B4 (de) * 2014-10-24 2019-07-04 Danfoss Silicon Power Gmbh Leistungshalbleitermodul mit kurzschluss-ausfallmodus
DE102017115701B4 (de) * 2017-07-12 2022-03-03 Lts Lohmann Therapie-Systeme Ag Fampridin-TTS

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE82916B1 (en) * 1990-11-02 2003-06-11 Elan Corp Plc Formulations and their use in the treatment of neurological diseases
US5977131A (en) 1997-04-09 1999-11-02 Pfizer Inc. Azaindole-ethylamine derivatives as nicotinic acetylcholine receptor binding agents
AU2002250307A1 (en) * 2001-03-14 2002-09-24 The Government Of The United States Of America, As Represented By The Secretary Of Health And Human Improving postsynaptic response by a combination of 4-minopyridine and agonist
US8007826B2 (en) * 2003-12-11 2011-08-30 Acorda Therapeutics, Inc. Sustained release aminopyridine composition
US8354437B2 (en) * 2004-04-09 2013-01-15 Acorda Therapeutics, Inc. Method of using sustained release aminopyridine compositions

Also Published As

Publication number Publication date
US20160213661A1 (en) 2016-07-28
CN102143687B (zh) 2015-11-25
MX2012001814A (es) 2012-06-01
WO2011019845A1 (en) 2011-02-17
UY32837A (es) 2011-03-31
US20190247379A1 (en) 2019-08-15
CN102143687A (zh) 2011-08-03
RU2012108656A (ru) 2013-09-20
HK1173911A1 (zh) 2013-05-31
ES2563751T3 (es) 2016-03-16
US20170281608A1 (en) 2017-10-05
US20170056385A1 (en) 2017-03-02
AU2010282509B2 (en) 2015-07-30
CA2770698C (en) 2018-01-30
US20130053420A1 (en) 2013-02-28
US20190015399A1 (en) 2019-01-17
KR20120050473A (ko) 2012-05-18
US20200113882A1 (en) 2020-04-16
AU2010282509A1 (en) 2012-03-01
EP2464229B1 (en) 2015-11-25
TW201110967A (en) 2011-04-01
JP2016074728A (ja) 2016-05-12
EP2464229A1 (en) 2012-06-20
ZA201201001B (en) 2014-10-29
TWI549678B (zh) 2016-09-21
RU2563821C2 (ru) 2015-09-20
JP2013501805A (ja) 2013-01-17
JP6137833B2 (ja) 2017-05-31
EP2464229A4 (en) 2013-02-13
BRPI1003991A2 (pt) 2015-09-15
US20180147193A1 (en) 2018-05-31
TW201613585A (en) 2016-04-16
JO3348B1 (ar) 2019-03-13
CA2770698A1 (en) 2011-02-17
AR077858A1 (es) 2011-09-28

Similar Documents

Publication Publication Date Title
KR20170128633A (ko) 탈수초성 질환 및 다른 신경계 질환을 앓는 환자에서 신경-인지 및/또는 신경-정신 손상을 개선하기 위한 4-아미노피리딘의 용도
KR20140054129A (ko) 라퀴니모드와 인터페론-베타의 병용에 의한 다발성 경화증의 치료
HK1226940A1 (zh) 用拉喹莫德与醋酸格拉替雷的组合治疗多发性硬化症
KR20150003765A (ko) 라퀴니모드와 디메틸 푸마레이트의 병용물에 의한 다발성 경화증의 치료
CN115776894A (zh) T型钙通道调节剂的使用方法
TW201010703A (en) Methods of using sustained release aminopyridine compositions
KR20150038072A (ko) 라퀴니모드와 팜프리딘의 병용물에 의한 다발성 경화증의 치료
KR20120050512A (ko) 탈수초를 갖는 환자에서 ４-아미노피리딘을 사용한 지속적 치료
JP2023526634A (ja) 高アンモニア血症を治療するためのオルニチンフェニルアセテートの使用
AU2015305430A1 (en) Method for treating hyperhidrosis
AU2012276476A1 (en) Pharmaceutical composition for treating premature ejaculation and method for treating premature ejaculation
HK1173911B (en) Use of 4-aminopyridine to improve neuro-cognitive and/or neuro-psychiatric impairment in patients with multiple sclerosis
OA16802A (en) Pharmaceutical composition for treating premature ejaculation and method for treating premature ejaculation.

Legal Events

Date Code Title Description
A107 Divisional application of patent
A201 Request for examination
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20171114

Application number text: 1020127006244

Filing date: 20120309

PA0201 Request for examination
PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20180118

Patent event code: PE09021S01D

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20200117

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20200916

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20200117

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

Patent event date: 20180118

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I